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Abstract
The Rank Forum on Vitamin D was held on 2nd and 3rd July 2009 at the University of Surrey, Guildford, UK. The workshop consisted of a series
of scene-setting presentations to address the current issues and challenges concerning vitamin D and health, and included an open discussion
focusing on the identification of the concentrations of serum 25-hydroxyvitamin D (25(OH)D) (a marker of vitamin D status) that may be
regarded as optimal, and the implications this process may have in the setting of future dietary reference values for vitamin D in the UK.
The Forum was in agreement with the fact that it is desirable for all of the population to have a serum 25(OH)D concentration above
25 nmol/l, but it discussed some uncertainty about the strength of evidence for the need to aim for substantially higher concentrations
(25(OH)D concentrations . 75 nmol/l). Any discussion of ‘optimal’ concentration of serum 25(OH)D needs to define ‘optimal’ with care
since it is important to consider the normal distribution of requirements and the vitamin D needs for a wide range of outcomes. Current UK
reference values concentrate on the requirements of particular subgroups of the population; this differs from the approaches used in other
European countries where a wider range of age groups tend to be covered. With the re-emergence of rickets and the public health burden
of low vitamin D status being already apparent, there is a need for urgent action from policy makers and risk managers. The Forum highlighted
concerns regarding the failure of implementation of existing strategies in the UK for achieving current vitamin D recommendations.
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The Rank Forum on Vitamin D was held on 2nd and 3rd
July 2009 at the University of Surrey, Guildford, UK.
The workshop consisted of a series of scene-setting
presentations to address the current issues and challenges
concerning vitamin D and health, and then an open discus-
sion followed. The discussion focused on the identification
of the concentrations of plasma 25-hydroxyvitamin D
(25(OH)D), a marker of vitamin D status, that may be
regarded as optimal, and the implications this process
may have in the setting of future dietary reference values
(DRV) for vitamin D in the UK. The implications of any
changes in the present recommendations on vitamin D
were also considered. The sessions were co-chaired by
S. A. L.-N. of the University of Surrey and J. L. B. of the
British Nutrition Foundation. L. M. M. from the British
Nutrition Foundation was the Forum Rapporteur. Professor
C. M. W. (University of Reading and Rank Prize Fund
Committee) acted as overall Forum Chair.
Background
Vitamin D can be obtained from dietary sources in two
main forms, namely ergocalciferol (vitamin D2) and
cholecalciferol (vitamin D3). Vitamin D is also produced
photochemically in the skin in the form of vitamin D3. The
action of sunlight (UV radiation of wavelength 290–310nm)
converts 7-dehydrocholesterol to vitamin D3 (via its precur-
sor). The liver enzyme 25-hydroxylase converts endogen-
ously synthesised vitamin D3 and diet-derived D2 and D3 to
25(OH)D. In the kidney, 25(OH)D can be converted to
1,25-dihydroxyvitamin D, the active hormone which acts in
concert with parathyroid hormone and calcitonin to main-
tain plasma Ca concentrations through homoeostatic regu-
lation. 25(OH)D is the major circulating metabolite of
vitamin D, with a half-life of several weeks, and therefore,
it is considered to be a valid indicator of vitamin D status.
Serum 1,25-dihydroxyvitamin D is tightly regulated, only
falling in extreme deficiency. Traditionally, a serum
25(OH)D concentration below 25nmol/l has been regarded
as an index of increased risk of overt bone disease and
hence as vitamin D ‘deficiency’, and this has been used as
the criterion for determining adequacy of vitamin D supply
and for settingDRV in theUK.Prolongeddeficiencyof vitamin
D results in osteomalacia in adults and in rickets in children.
There are very few dietary sources of vitamin D, with
oily fish being the richest source of the nutrient. However,
in the UK, only 27 % of the population are consumers of
oily fish(1). Other dietary sources include eggs, meat and
fortified products such as margarine, reduced fat spreads
and some breakfast cereals. Since 1940, there has been
mandatory fortification of margarine with vitamin D in
the UK (to bring the concentration of vitamin D to that
of butter); many reduced fat spreads are also voluntarily
fortified with vitamin D. Dietary vitamin D can be present
as either vitamin D2 or vitamin D3.
Fig. 1 shows that low vitamin D status is prevalent in the
UK, and that it is particularly marked in young and older
adults and in ethnic minorities(2,3). Although once thought
of as a disease of the past, the re-emergence of rickets
is evident in some subgroups of the population in the
UK(4), predominantly in those of African–Caribbean and
South Asian origins. Government advice(4–6) is for Asian
children and women to take supplementary vitamin D.
The high prevalence of vitamin D insufficiency among
people of African–Caribbean and South Asian origin,
especially children, adolescents and women, is likely to be
due to a combination of factors including consumption of a
vegetarian diet poor in vitamin D, low Ca intake and limited
sunlight exposure(4). In a study of UK pregnant women
from ethnic minorities, Datta et al.(7) reported that . 50%
had a serum 25(OH)D concentration , 25nmol/l. In
southern England, 18% of pregnant White women had a
serum 25(OH)D concentration , 25nmol/l, and 31% had
serum 25(OH)D concentration , 50nmol/l(8), showing that
the problem is also present in the white Caucasian popu-
lation(9). In addition, the UK Government’s Scientific Advisory
Committee on Nutrition (SACN) highlighted that young
women of childbearing age throughout the population
may have low vitamin D stores during the initial stages of
pregnancy, and that many older people may have poor
vitamin D status especially those in institutional care. Current
government advice is for pregnant women, infants, young
children and those over 65 years of age to supplement their
diet with vitamin D(4–6). However, as will be discussed later,
compliance with this advice is poor.
In recent years, the link between sunlight exposure
and skin cancer risk has been recognised and, as a result,
regular use of sunscreen has been advised and groups at
particular risk such as young children and older people
have been advised to ‘cover up’. This public health
advice may have influenced skin synthesis of vitamin D
adversely. Few studies have attempted to quantify skin
UVB exposure typical of the UK population, but several
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Fig. 1. Prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D
concentrations , 25 nmol/l) in people in the UK(2,3). F, free-living; I, institutio-
nalised. British Asians were defined as those of South Asian origin
(Pakistani, Indian and Bangladeshi). Source(11,62,64). B, Males; B, females.
Proceedings of the Rank Forum on Vitamin D 145
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
studies funded by the Food Standards Agency (FSA) are
now underway (see Ireland (Cork), Aberdeen and Surrey
studies for more details.)
The current UK DRV for vitamin D are summarised
in Table 1. These were first derived in 1991 by the Committee
on Medical Aspects of Food and Nutrition Policy (COMA)(5),
and have since been endorsed by a 1998 COMA report on
nutrition and bone health(6). These were reviewed by the
SACN in their position statement in 2007(4), which considered
that there was insufficient evidence to change the DRV
at that time. The high prevalence of low vitamin D status in
the UK has led to speculation about the appropriateness
of the current UK DRV and, in particular, about the absence
of a reference nutrient intake (RNI) for people aged between
4 and 65 years in the general population, other than for
those at a specific risk of limited UVB skin exposure.
For those groups for whom RNI exist (Table 1), food
consumption surveys indicate that 97% of free-living older
people and 99% of institutionalised older people, for
example, have dietary vitamin D intakes below the RNI(10).
Low vitamin D status as defined by a cut-off value of
25 nmol/l for circulating 25(OH)D concentration is now a
major public health problem in the UK, and there have
been many calls for urgent action, including a revision of
DRV, revised advice regarding the risks to health linked
to sun exposure, and implementation of fortification
and supplementation programmes(11–13). However, at the
same time, a controversy has emerged regarding the opti-
mal range of serum 25(OH)D concentrations and the
threshold concentration of 25(OH)D below which there
are increased risks to health. To date the cut-off value
used is 25 nmol/l, which is based on the risk of (or the
absence of) rickets and osteomalacia. Proponents of setting
this threshold at a higher concentration than 25 nmol/l base
this on the potential for benefits in relation to a number of
chronic diseases, including osteoporosis, diabetes, CVD
and some cancers, and for ‘optimising’ immune function.
For example, following a meta-analysis of observational
studies, the International Association for Research on
Cancer(14) has concluded that an increased risk of colorec-
tal cancer and colorectal adenoma is associated with serum
25(OH)D concentrations below 40 nmol/l. Therefore, the
emergence of evidence for additional health benefits
associated with higher concentrations of plasma 25(OH)D
raises a number of issues that challenge the perceptions
about the current general health of the population.
There is already widespread evidence of poor vitamin D
status in the UK on the basis of the 25 nmol/l cut-off
value (see Fig. 1), and if the threshold value for
25(OH)D sufficiency were to be raised above 25 nmol/l,
for example to 40 nmol/l or higher, the proportion of the
population described as vitamin D deficient would
increase substantially. For example, data obtained from
the 1958 British birth cohort show evidence of a high
prevalence of low vitamin D status in adults aged 45
years. Using the 25 nmol/l cut-off value, the prevalence
(winter and spring combined) in 2003 was 15·5 %, but
this increased to 46·6 % at a cut-off value , 40 nmol/l and
to 87·1 % at a cut-off value , 75 nmol/l(15).
The Rank Forum on Vitamin D aimed to facilitate an
open discussion about the current controversies surround-
ing vitamin D and health by bringing together forty scien-
tists and health professionals, who were either actively
engaged in vitamin D research or had a particular interest
in the vitamin D field. The ultimate aim was to try to ident-
ify specific strategies and areas of common agreement with
a view to moving the field forward, recognising that there
are conflicting views and differing conclusions regarding
the strength of the evidence for the role of vitamin D in
the prevention of various chronic diseases.
An overview of vitamin D: controversial issues
B. J. B. (Queen Mary University of London, UK) outlined
some of the current controversies regarding hypo-
vitaminosis D and ill health, such as the variability in the
assessment of repletion and sufficiency of vitamin D, and
indicated that much of this variability is likely to be due
to the wide range of functions that vitamin D supports in
the body, often through local activation systems in target
tissues that themselves contain vitamin D receptors. It is
also clear that although there are known differences
and similarities between vitamin D2 and D3, there are
also areas of uncertainty regarding the functional differ-
ences of the two forms. B. J. B. also discussed the many
different factors contributing to the widespread problem
of low vitamin D status in the population, and highlighted
the fact that assessing vitamin D status can be particularly
challenging in pregnancy because early increases in decid-
ual and placental vitamin D 1-a hydroxylase activity
lower maternal 25(OH)D concentrations. Questions about
the possible adverse effects of being in the highest part
of the range of naturally occurring vitamin D status and
about the most appropriate doses of vitamin D to be
used in randomised controlled trials (RCT) were also
raised, together with the likelihood of variation in vitamin
D requirements with ethnicity and various genetic factors.
Vitamin D and the Finnish experience
C. L.-A. (University of Helsinki, Finland) initiated a discus-
sion regarding vitamin D fortification by presenting, as an
Table 1. Current UK reference nutrient intakes for vitamin D (mg/d)(5,6)
Age Males Females
0–6 months 8·5 8·5
7 months to 3 years 7 7
4 years to 65 years 0* 0
65 þ years 10 10
Pregnancy – 10
Lactation, 0–4 months – 10
Lactation, 4 þ months – 10
* 10mg/d for individuals who are at risk of inadequate UVB sunshine exposure.
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example, the Finnish experience of voluntary milk
fortification. C. L.-A. summarised the Nordic dietary vitamin
D recommendations (7·5mg/d for those aged 3–60 years
and 10mg/d for those aged , 3 and . 60 years) and the
problems of low vitamin D status among the Finnish
population. She discussed the simulation calculations for
different fortification options that had been considered
in Finland; these included fortification of milk, bread,
spread and cheese products. Consequently, the Finnish
Ministry of Trade and Industry launched a new decree on
optional (voluntary) fortification, which came into oper-
ation in February 2003. This allowed all fluid milk products
to be fortified with 0·5mg vitamin D3/100 ml and all spreads
to be fortified with 10mg vitamin D3/100 g. C. L.-A. also
presented the results of the DESE study, which compared
vitamin D status of the Finnish population in 2002 and
2004. It was shown that vitamin D status improved mark-
edly in those using fortified fluid milk products. Among
individuals not using vitamin D supplements, use of forti-
fied foods resulted in the percentage of individuals with
25(OH)D concentrations , 40 nmol/l falling from 44·8
to 27·7 %, and the percentage of individuals with serum
25(OH)D concentrations , 25 nmol/l falling from 2·4 to
0·4 %(16). Overall, vitamin D status improved in all groups
of the population, but it did not reach the recommended
targets in all subgroups of the population.
Dietary calcium, vitamin D status and fracture
C. N. (Deakin University, Australia) reviewed and pre-
sented the evidence on dietary Ca, vitamin D and fracture
risk, with a focus on older people. The majority of the RCT
that have intervened using oral vitamin D to assess the risk
of fracture also included supplementary Ca as part of the
supplementation regimen. C. N. presented data to show
that there is sufficient evidence to support the effectiveness
of either vitamin D or Ca supplementation in the reduction
of the risk of fractures in older women. A meta-analysis of
twelve RCT showed that a 20mg dose of vitamin D per day
is required to maintain vitamin D status and reduce the
risk of fractures, and that this effect is independent
of additional Ca supplementation(17). A further meta-
analysis of seventeen RCT(18) investigating the effect of
supplementation of Ca alone and combined supplemen-
tation of Ca and vitamin D on the risk of fractures
showed a 12 % decrease in risk (all studies combined).
Subgroup analyses showed that there was no difference
in risk reduction in the studies in which only Ca was
supplemented and those in which Ca and vitamin D
were supplemented together, suggesting that it is the Ca
(at a dose of . 1000 mg/d) that is driving the reduction
in the risk of fracture. On the other hand, other
work(19,20) has suggested that vitamin D dosage was
usually too low (,700 IU/d; ,17·5mg/d); also, since
most studies used the combined supplementation of
vitamin D and Ca, it is unclear to what extent the beneficial
effects of vitamin D supplementation on falls and fracture
may reflect the specific effect of a relatively high intake
of dietary Ca or, alternatively, the dependence of vitamin
D on adequate Ca intake for it to be effective. It should
also be noted that compliance with Ca supplementation
is known to be challenging, which has been a confounding
factor in many such trials.
Global vitamin D requirements
K. D. C. (University College Cork, Ireland) gave an
overview of vitamin D requirements from a global perspec-
tive. Most recommendations in relation to vitamin D
are based on promoting ‘health’ and preventing deficiency
as assessed based on serum 25(OH)D concentration.
He argued that summer sunlight is a much more potent
source of vitamin D than the diet, but that diet takes on
an increasing importance during winter at latitudes greater
than 408N or S due to the unavailability of UVB radiation
of sufficient strength to stimulate dermal synthesis of the
vitamin. According to the FAO/WHO(21), it is clear that at
about equatorial latitudes (428N–428S), sun exposure to
the face and arms for 30 min/d is the most efficient way
of maintaining adequate vitamin D status. However, out-
side these latitudes, exposure for 30 min/d is only effective
in summertime for the reasons mentioned above, and
furthermore, the dermal capacity of skin to synthesise
vitamin D is impacted upon by a range of factors other
than latitude such as ageing, skin pigmentation, the use
of sunscreen, cloud cover, sun avoidance and various
degrees of cover from clothing. Despite these consider-
ations, many countries still make an assumption that sun
exposure in summer will provide an amount sufficient
for adequate vitamin D status all year round. Dietary vita-
min D recommendations are variable across Europe (see
Table 2) and also globally. Most countries have no official
specific recommendations for ethnic minority groups. In
many countries, dietary intakes of vitamin D are far
lower than the national/regional recommendations(22).
The UK Scientific Advisory Committee on Nutrition
position on vitamin D
E. M. S. (UK FSA) presented the view of SACN regarding
vitamin D recommendations and requirements. SACN has
succeeded COMA as the group of scientific experts
charged with advising the UK government on scientific
risk assessment regarding nutrition. In 1991, COMA
published its DRV(5), which included DRV for vitamin D
(see Table 1). These values were endorsed by a second
COMA report on nutrition and bone health published in
1998(6), and in 2007, SACN published a position statement
entitled An update on vitamin D(4). This update assessed
whether there was sufficient accumulating new evidence
to support a need for a full review of DRV for vitamin D.
However, SACN’s update did not set out to provide
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a systematic review of the evidence on vitamin D and
health. SACN concluded that there was insufficient
evidence at that time to warrant a full review of UK
DRV for vitamin D, but reiterated the previous COMA
recommendations. SACN also highlighted the continued
need for a clear public health strategy and guidance on
vitamin D supplementation targeted at health professionals
and at-risk groups. The Committee also acknowledged
the accumulating, but as yet insufficient, evidence for an
inverse association between vitamin D and chronic disease
risk. SACN is now awaiting the results of a series of FSA-
funded research projects on vitamin D, in particular,
those investigating the relative importance of sunlight
and diet in the determination of vitamin D status of the
population. These were discussed at an FSA Workshop
on Vitamin D held in November 2009(23).
Vitamin D and bone health
A. P. (MRC-Human Nutrition Research, UK) gave a presen-
tation on vitamin D and bone health. A. P. described
the deficiency states of vitamin D: rickets in children
and osteomalacia in children and adults. Until its recent
re-emergence in some subgroups of the UK population
(particularly ethnic minorities), rickets has been regarded
as a disease of the past. Traditionally, the threshold for
identifying poor vitamin D status has been identified
using the cut-off values for 25(OH)D above which rickets
and osteomalacia would not be expected (.25 nmol/l in
the UK). Prevalence figures for this degree of low vitamin
D status in the UK were presented (see Fig. 1). Younger
and older adults and British Asians show the lowest vita-
min D status. Many ethnic groups across the world also
show evidence of poor vitamin D status in pregnancy(24).
The main dietary sources of vitamin D in the UK were
also presented (see Table 3). The differences and simi-
larities between vitamin D2 and D3 were highlighted (for
example, similarities in absorption from the gastrointestinal
tract and differences in the rates of disappearance from the
circulation and in their metabolism and breakdown) as
well as their usefulness in treating clinical vitamin D
deficiency. However, uncertainties about their relative effi-
cacies remain because of inconsistencies in the evidence.
For example, Trang et al.(25) reported that vitamin D3 is
Table 2. Overview of the recommendations, by age, for dietary intake of vitamin D (mg/d) for selected population groups in Europe (males and
females)(61)*
Population groups (age)
Year Country 3 months 9 months 5 years 10 years 15 years 25 years 50 years 70 years
2005 Albania 5 5 5 5 5 10 10
2006 Belgium 12·5 12·5 7·5 6·3 6·3 6·3 6·3 10
2005 Bulgaria 5 5 5 5 5 5 5 10
2004 DACH countries† 10 10 5 5 5 5 5 5
2006 Estonia 10 7·5 7·5 7·5 7·5 7·5 10
2001 France 22·5 22·5 5 5 5 5 5 5
2005 Hungary 10 10 10 10 10 5 5 5
2006 Iceland 10 10 10 10 10 10 15
1999 Ireland 8·5 7 5 5 7·5 5 5 10
1996 Italy 17·5 5 5 7·5 5 5 10
2001 Latvia 10 10 10 10 10 5 5 5
1999 Lithuania 10 10 5 5 5 5 5 5
2000 Netherlands 5 5 2·5 2·5 2·5 2·5 2·5 7·5
2004 Nordic countries‡ 10 7·5 7·5 7·5 7·5 7·5 10
1996 Poland 10 10 10 10 10 5
1990 Romania 10 10 10 10 7·5 5 5 5
1991 Russian Federation 10 10 2·5 2·5 2·5 2·5 2·5 2·5
1994 Serbia 10 10
1997 Slovakia 7·5 10 7·5 7·5 10 7·5 5·8 5
2007 Spain 10 10 10 5 5 5 10 15
2001 The former Yugoslav Republic of Macedonia 7·5 10 10 10 10 5 5 5
1991 United Kingdom 8·5 7 0§ 0§ 0§ 0§ 0§ 10
1993 European Commission 17·5 5 5 7·5 5 5 10
2004 WHO/FAO 5 5 5 5 5 5 5 15
* Croatia, Federation of Bosnia and Herzegovina and Republic of Srpska (entities of Bosnia and Herzegovina) and Montenegro are excluded from the table because no
recommendation report was available to the author, and the Czech Republic is excluded due to the lack of a published data source.
† DACH countries are Austria, Germany and Switzerland.
‡ Nordic countries are Denmark, Finland, Iceland, Norway and Sweden.
§ 10mg/d for those at risk of limited UVB skin exposure.
Table 3. Dietary sources of vitamin D in the UK(62)
Source
Contribution to
dietary intakes
in women (%)
Contribution to
dietary intakes
in men (%)
Cereal and cereal products 22 20
Milk and milk products 3 2
Egg and egg dishes 9 10
Fat spreads (including
fortified margarine)
15 19
Meat and meat products 18 24
Fish and fish dishes 30 21
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more effective than vitamin D2 at raising total 25(OH)D,
but Holick et al.(26) have suggested that there is little differ-
ence in their biological efficacy in this regard. There is also
some debate about the use of biomarkers as measures of
vitamin D status. A. P. concluded that serum 25(OH)D is
a useful biomarker of supply to target tissues, though
many factors influence its use as a biomarker of function
and, most importantly, that the ongoing debate on the opti-
mal level of serum 25(OH)D should not hinder progress
towards the introduction of steps to combat vitamin D
deficiency as laid down in current guidelines.
Significance of dietary intake and sunlight in
determination of vitamin D status
M. K. (University College Cork, Ireland) put the new
data she was presenting into context by reviewing a semi-
nal study done by Heaney et al.(27), which showed
that healthy men relied substantially on tissue stores of
cholecalciferol from previous sun exposure to meet their
wintertime vitamin D requirement, and that an additional
minimum of 12·5mg/d vitamin D3 would be needed
to maintain autumn concentrations of serum 25(OH)D
throughout winter. However, the slope of the relationship
between cholecalciferol dose and serum 25(OH)D was
approximately 0·7 nmol/l for each microgram of vitamin D3
consumed, indicating an average requirement of approxi-
mately 114mg/d to achieve a 25(OH)D level of 80 nmol/l.
In the context of these data and the current SACN
recommendations for vitamin D in UK adults aged below
65 years, M. K. reported the results of two studies funded
by the FSA investigating the hypothesis that there is a diet-
ary requirement for vitamin D to prevent deficiency during
wintertime in adults. The studies aimed to determine the
total daily vitamin D intake needed to prevent vitamin D
deficiency (serum 25(OH)D concentration , 25 nmol/l),
and to provide data on the relative importance of diet
and sunlight in determining vitamin D status in adults.
These were two double-blind RCT involving healthy
adults aged 20–40 (n 238) and . 64 (n 225) years who
were supplemented with 5, 10 or 15mg/d vitamin D3
during two successive winters; the control group did not
receive supplemental vitamin D3. The studies were desi-
gned to produce data showing a distribution of serum
25(OH)D levels at endpoint arising from inter-individual
variation in dose, habitual diet and sun exposure during
the preceding summer, from which the relationship
between vitamin D3 intake and early spring status could
be examined. The data confirmed the original hypothesis,
and showed that 8·7mg/d (adults aged 20–40 years) and
8·6mg/d (adults aged . 64 years) of dietary vitamin D3
were needed to maintain 97·5 % of the population (i.e.
RNI) above a threshold of 25 nmol/l of 25(OH)D through
the winter(28,29). An individual’s preference for sun
exposure had a major effect on these results; 20–40 year
olds who reported avoiding the sun had an RNI of
12·3mg/d and those aged . 64 years who reported
receiving , 15 min of sun exposure/d during summer
had an RNI of 11·4mg/d. The data were also used to pre-
dict intakes of vitamin D3 that would maintain winter-
time 25(OH)D at higher thresholds, including 50 and
80 nmol/l, although M. K. recommended the implemen-
tation of a new study using a similar design with higher
doses of vitamin D to confirm these predictions, particu-
larly for the 80 nmol/l cut-off value.
Longitudinal study of diet and sunlight interactions
in north-east Scotland
H. M. M. and A. M. (University of Aberdeen, UK)
highlighted some issues surrounding poor vitamin D
status and seasonality from a Scottish perspective. They
presented preliminary results obtained from a 15-month
longitudinal study of diet and sunlight interactions
funded by the FSA and conducted in Aberdeen (Aberdeen
Nutrition, Sunlight and Vitamin D Study), with W. D. F.
(University of Liverpool, UK) measuring 25(OH)D for the
study. In order to determine whether post-menopausal
women in the north of the UK have worse vitamin D
status than their counterparts living in the south of the
country, and to assess whether the sunlight and dietary
contributions are different according to latitudinal residen-
tial position, the related FSA-funded study by the Surrey
group (see later) used the same study design. This allowed
a direct comparison across the same year (summer 2006 to
spring 2007). An additional measurement of 25(OH)D was
made in spring 2008 to determine whether the poor
summer of 2007 had any impact on vitamin D status in
the following spring.
Vitamin D, food intake, nutrition and exposure to sunlight
in Southern England (Vitamin D, Food Intake, Nutrition
and Exposure to Sunlight) study
S. A. L.-N. and A. L. D. (University of Surrey, UK) presented
some preliminary findings from the Vitamin D, Food
Intake, Nutrition and Exposure to Sunlight study in
Southern England funded by the FSA. This study was con-
ducted in collaboration with the University of Manchester,
and it investigated the effects of ethnicity and menopausal
status on vitamin D status and on the relative contributions
of dietary intake of vitamin D and UV sunlight exposure
to vitamin D status. The impact of vitamin D status on
functional markers of bone health and the relative contri-
bution of diet and sunlight exposure to the vitamin D
status of ethnic groups were also determined. A total of
eighty-six Asian women and 270 Caucasian women aged
18–69 years (pre- and post-menopausal) were recruited,
with data being collected in each season for one
12-month period (summer 2006 to spring 2007). Full
data were collected on seventy Asian women and 223
Caucasian women.
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Vitamin D methodology project
M. A. (Ashwell Associates, UK) gave an overview of a
new study funded by the FSA, entitled How can we stan-
dardise the measurement of serum 25(OH)D in national
surveys? This work was commissioned in response to a
recommendation by SACN(4) to urgently resolve the lack
of standardisation between laboratories and methodologies
regarding measurement of serum 25(OH)D. A comprehen-
sive, critical review of all recent publications on the assays
used for 25(OH)D was completed, and the most robust
method was recommended for use in the next UK National
Diet and Nutrition Survey. The results of the comprehen-
sive review were discussed at the FSA Workshop on
Vitamin D in November 2009(30,31).
Vitamin D and diabetes
E. H. (Institute of Child Health, UK) presented the latest
evidence on vitamin D and diabetes. It has been purported
that vitamin D can reduce the risk of both type 1 and type 2
diabetes(32). It is thought that the risk of type 1 diabetes can
be influenced by vitamin D through immunomodulation
(via vitamin D receptors in macrophages and monocytes),
and the risk of type 2 diabetes can be influenced by
increased production of insulin (via vitamin D receptors
in the pancreas) or because 1,25-dihydroxyvitamin D
produced in the kidney enters the circulation and can
down-regulate renin production in the kidney and stimu-
late insulin secretion in the islet b-cells of the pancreas.
E. H. reviewed the scientific evidence to support these
hypotheses, and highlighted several gaps and limitations.
Overall, she concluded that there is support for an inverse
association between vitamin D and type 1 diabetes(33,34),
with the strengths of the evidence base including temporal
relevance, evidence of a dose–response effect, biological
plausibility and fair consistency across studies. However,
causality for the role of vitamin D in type 1 diabetes has
not been demonstrated. For type 2 diabetes, the main
gap is the lack of well-controlled experiments; randomised
trials of the effects of vitamin D on glycaemic control or
type 2 diabetes prevention have provided inconsistent evi-
dence, generally reporting no effect(35,36). There are some
cross-sectional data to support an association between
vitamin D and type 2 diabetes/related phenotypes(37),
and some longitudinal studies also offer support(38),
though these are often limited by the lack of ability to
fully adjust for strong confounders such as adiposity.
Vitamin D and immune function
A. R. M. (Queen Mary University of London, UK) presented
evidence on vitamin D and immune function. Much of the
evidence is based on the association between vitamin D
deficiency and susceptibility to active tuberculosis(39);
indeed, vitamin D was used to treat tuberculosis in the
pre-antibiotic era. It has been reported that calcitriol
(1,25-dihydroxyvitamin D3) enhances the ability of leuco-
cytes to suppress the growth of mycobacteria in vitro,
and that this is associated with the induction of cathelicidin
LL-37, which possesses anti-tuberculous activity(40,41).
A clinical trial has shown that a single oral dose of
2·5 mg vitamin D2 enhances the ability of whole blood
taken from tuberculosis contacts to restrict mycobacterial
growth in vitro (42), but that it was insufficient to maintain
vitamin D sufficiency for 8 weeks in tuberculosis
patients(43). A. R. M. concluded by commenting that a
number of clinical trials of vitamin D supplementation for
the prevention and treatment of various respiratory infec-
tions are underway, and that findings from these studies
will be important for the this area of research to progress.
The concentration of circulating 25-hydroxyvitamin D
that can be regarded as optimal
The final two presentations by R. V. (University of Toronto,
Canada) and R. M. F. (University of Newcastle, UK) set
the scene for an open discussion. These presentations
focused on the identification of the serum concentration
of 25(OH)D that should be selected as the criterion for
judging the adequacy of vitamin D supply in the UK, and
highlighted the various considerations that need to be
taken into account.
R. V. showed a series of data obtained from cross-
sectional studies that indicated an association between
25(OH)D and bone mass and bone mineral density/
content in girls. He also showed results obtained from a
study investigating the long-term efficacy and safety of
high vitamin D intakes delivered via fortified bread to
older adults. In this study, Mocanu et al.(44) reported that
serum 25(OH)D increased with 5000 IU/d (125mg/d)
vitamin D, which was also associated with a significant
improvement in hip bone mineral density. Several observa-
tional studies have reported an association between low
25(OH)D status and increased CVD risk. Many of these
studies have been cross-sectional, but there is some pro-
spective evidence showing an association between low
25(OH)D status and higher risk of myocardial infarction(45).
Data were also presented showing some inconsistencies
regarding vitamin D and prostate cancer risk, indicating
that both low and high 25(OH)D statuses are associated
with an increased risk(46). These findings have been
linked to a hypothesis that cycles of rising and falling
25(OH)D concentrations contribute to cancer risk. R. V.
highlighted some limitations of the RECORD trial(47), in
which no decrease in falls, fractures or mortality in older
men and women with a low trauma fracture was found
with vitamin D supplementation, in particular, poor com-
pliance with the intervention. He also argued that other
studies show more positive results for vitamin D and
fracture risk.
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R. V. indicated that several authors have estimated
different optimal serum 25(OH)D concentrations in
relation to individual or multiple health outcomes.
Dawson-Hughes et al.(48) generated a consensus statement
suggesting a lower threshold vitamin D3 status of
about 75 nmol/l 25(OH)D (equivalent to an intake of
800–1000 IU/d or 20–25mg/d).
In terms of potential toxicity, R. V. proposed that an
intake of up to 10 000 IU/d (250mg/d) of vitamin D3 is
physiological and safe because it matches the effects of
exposure to natural UVB in sunlight on 25(OH)D concen-
trations. He described a series of potential toxicities
in which vitamin D had been implicated, and produced
evidence to dispute these data. Hathcock et al.(49) have
also reported the absence of toxicity in trials involving
normal adults using vitamin D dosages at and above a
level of 250mg/d (10 000 IU vitamin D3). These data were
used to argue about the selection of this value as the
upper level that could be taken without the risk of toxic
exposures. Furthermore, R. V. considered there to be no
evidence of an adverse effect of serum 25(OH)D up
to 400 nmol/l, and on this basis, he suggested that
supplements of 4000 IU/d (100mg/d) could be considered
as safe.
R. M. F. highlighted the difficulty in determining what
constitutes optimal vitamin D status for bone health. For
example, though there is an inverse relationship between
serum 25(OH)D and parathyroid hormone, there is no
threshold of 25(OH)D above which parathyroid hormone
reaches a plateau. He also discussed the findings of the
RECORD study(47) and the results of a recent Cochrane
review(50) that showed that vitamin D alone has no signifi-
cant effect on hip fracture (nine trials), but that combined
vitamin D and Ca supplementation (eight trials) reduced
hip fractures, especially in institutionalised older people.
Overall, R. M. F. concluded that there is evidence that
combined Ca and vitamin D supplementation decreases
fracture risk in institutionalised older people, a group in
whom vitamin D deficiency (serum 25(OH)D concen-
trations , 25 nmol/l) is common. Nevertheless, he
acknowledged that a number of authors have advocated
higher serum 25(OH)D concentrations for optimal
bone health, ranging from 50 to 80 nmol/l. He also recog-
nised that there may be skeletal and non-skeletal benefits
of increasing serum 25(OH)D concentrations above
75 nmol/l, but felt that this is still unproven, and expressed
concerns about the lack of data on the long-term safety of
high-dose vitamin D. He recommended focusing attention
on targeting groups at the highest risk of vitamin D
deficiency in order to ensure that serum 25(OH)D is kept
at least above the 25 nmol/l level.
Discussion
A number of themes emerged during the open discussion,
which are summarised below.
Our evolutionary past
It has been considered by many that humans evolved for
an outdoor lifestyle, and so the common problems
caused due to a poor vitamin D status may be a feature
of modern lifestyles as they diverge from those of our evol-
utionary past(51). Now, the demands of Western Society
seem to dictate a lifestyle that involves large amounts
of time spent indoors, and for many being sedentary is
the norm, i.e. the majority of occupations are now office-
based or in the service sector rather than manual work con-
ducted outdoors. Furthermore, risks associated with skin
cancer also mean that the public is now increasingly
aware of the dangers of excessive sun exposure. People
with outdoor lifestyles, such as lifeguards, tend to have
higher serum 25(OH)D concentrations(51), and therefore,
the sunlight exposure that might be a ‘normal’ level for an
outdoor worker may differ from that for an older person
who spends a great deal of time indoors.
Optimal concentrations of serum 25-hydroxyvitamin D
The group was in agreement with the fact that it is
desirable for all the population to have a serum 25(OH)D
concentration above 25 mmol/l. There was considered to
be some uncertainty about the strength of evidence for
the need to aim for substantially higher concentrations
(25(OH)D concentrations .75 nmol/l). Much of the data
that are used to support a higher target level of 25(OH)D
are based on cross-sectional or, at best, observational
cohort data, and there is a need for further evidence
from RCT. The majority of this observational evidence
that is related to health outcomes other than bone is epide-
miological, and is thus unable to establish causality
directly, especially given the major problems caused by
confounding in many such studies. A further limitation of
science in this area is the inappropriate extrapolation of
the study results obtained from one country to another,
when they lie at different latitudes or altitudes and have
different customary styles of dress and lifestyle and are
therefore exposed to different levels of sunlight and UVB.
It was agreed that any discussion of ‘optimal’ concen-
tration of serum 25(OH)D needs to define ‘optimal’ with
care since it is important to consider the normal distri-
bution of requirements and the requirements for a wide
range of outcomes. For population health, the aim is to
identify targets that 97·5 % of the population should
achieve. If 25(OH)D concentration # 25 nmol/l defines
the bottom 2·5 percentile of the normal distribution, then
an important consideration is to determine what the
median and 97·5 percentile values should be. Future
discussions regarding ‘optimal’ levels of serum 25(OH)D
require clarification on the definition of ‘optimal’ in terms
of the normal distribution of requirements; currently,
consensus is only available on the lower 2·5 % value
(25 nmol/l), though this is an important cut-off value as it
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defines overt bone risk and it has been shown that
supplementation at the population level can raise the
majority of the population above this cut-off value. Further-
more, DRV are designed for use in monitoring the dietary
adequacy of populations and not for gauging individual
risk. When serum 25(OH)D concentration is used to
assess individual vitamin D status, other considerations
also come into play, such as the period of time over
which the concentration has been at the measured level,
individual variability in vitamin D requirements and
whether there are physiological factors that affect the
interpretation of plasma concentrations of vitamin D.
Considerations for potential supplementation and
fortification programmes
A number of issues need to be considered before any
(mass) supplementation or population-level fortification
programme could be implemented. It is known that
compliance/concordance with oral vitamin D (especially
when given with Ca) supplements is poor in the clinical
setting, particularly in older people, and there are also
some uncertainties that remain regarding potential adverse
effects of high doses. High-dose (4000 IU/d; 100mg/d)
supplements have not been used in the UK; thus, there
are no compliance data available to assess their use. The
presentation by C. L.-A. highlighted a number of issues
that are to be considered before a voluntary fortification
programme is implemented (for example, choice of
fortificant, bioavailability, technical issues related to
adding vitamin D to foods and current intake levels of
fortificant). In Finland, more comprehensive dietary rec-
ommendations for vitamin D were also available than
those that currently exist in the UK. It was considered
that if the UK were eventually to pursue a route of fortifi-
cation, further planning, modelling analyses and testing
of systems for supplementation would be needed before
there could be implementation across the population.
There is also a need to look at the long-term safety of
any proposed fortification programme. For example, in
the context of population-based fortification programmes,
R. M. F. referred again to the issue of the potential for
adverse effects in older people with undetected primary
hyperparathyroidism and in younger people with unrecog-
nised sarcoidosis.
Inter-individual variability in response to vitamin D.
Further research is needed to help understand possible
inter-individual differences in the metabolism of vitamin
D. Genetic polymorphisms affect vitamin D metabolism,
and may underlie inter-individual variability in status. It is
also possible that requirements for vitamin D intake are
affected by genetic variations, as many of the metabolic
effects of hormonal vitamin D are mediated via genomic
pathways; vitamin D receptors are located throughout
the body and a large number of other genes have
vitamin D response elements in their promoter regions.
The possibility of establishing a reference range for
serum 25(OH)D concentrations based on a threshold at
which serum parathyroid hormone concentration starts to
rise has been precluded by the large variation between
individuals and the multitude of factors affecting the circu-
lating concentrations of the analytes(52). It is important to
note that population-based considerations, such as DRV,
are designed to cover the needs of the general population
at large, and genetic variations are therefore not relevant
for policy setting unless an approach that is different
from that currently being used to set requirements is used.
Body stores of vitamin D and seasonality in ‘status’.
Seasonal fluctuation in vitamin D status is found in most
non-tropical populations. Therefore, it is important to
understand fully the mechanisms by which vitamin D is
stored in the body, so that it is possible to determine
whether stores of vitamin D derived from summer sunlight
are adequate to maintain the desired status throughout
the winter. It is known that vitamin D is stored in the
liver, adipose and muscle tissues, but whether these
stores act as a genuine reserve for vitamin D in the
winter months, whether the vitamin D in adipose and
liver tissues is fully labile and whether the speed of its
release from stores is a factor that determines the length
of time that stores in various individuals can help to main-
tain adequate status are not known; for example, fat stores
are thought to sequester vitamin D, lowering circulating
25(OH)D concentrations, but what happens over the
seasons or with weight loss in such subjects is ill-defined.
Safety of high doses of vitamin D. Research has not
provided sufficient information to understand the potential
toxicity of high doses of vitamin D. There is a clear need to
distinguish between the risks from high doses of vitamin D
derived from large exposures to sunlight (skin cancer) and
those that might arise from taking vitamin D in fortified
foods or as supplements, and to increase public under-
standing on these issues.
The human body is adapted such that it will not produce
too much vitamin D as a result of sunlight exposure.
Conversion of 7-dehydrocholesterol to previtamin D3 in
the skin is regulated so that prolonged sunlight exposure
does not lead to excess production. Production is shut
off once a particular threshold is reached, when there
is evidence of slight reddening of the skin. However,
extensive sun exposure of skin increases the risk of skin
cancer. Therefore, guidance on safe sun exposure in
relation to both skin cancer and vitamin D status is a
complex message to communicate to the public, and any
advice needs to be latitude-specific. Some success has
been achieved in Australia(53), and this could provide
useful lessons for other countries. In the UK, Cancer
Research UK no longer advocates total sun avoidance,
but it does recommend sunburn avoidance.
Very high doses of oral vitamin D supplements have
been found to have toxic effects in healthy people. Exces-
sive vitamin D activity leads to hypercalcaemia with severe
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toxicity, which can lead to renal failure and cardiac
arrest. The UK Expert Group on Vitamins and Minerals(54)
identified safe upper limits for consumption of vitamins
and minerals. They concluded that a level of 25mg/d of
supplementary vitamin D would not be expected to lead
to adverse effects when consumed regularly over a long
period. Around the same time, the EU Scientific Committee
on Food(55) could not establish a ‘no observed effect level’
or a ‘lowest observed adverse effect level’ because of
uncertainty in the data. However, a tolerable ‘upper
intake level’ was established at 25mg/d for infants and
children aged 10 years or less and 50mg/d for children
aged over 11 years old and adults. The US Standing
Committee on the Scientific Evaluation of Dietary Refer-
ence Intakes set an upper intake level of 25mg/d for infants
aged up to 12 months and an upper intake level of 50mg/d
for children aged 1–18 years and adults(56). More recent
evidence indicates that adverse effects are not found
until much higher doses are given, and that intakes of
100mg/d are safe(57).
Availability of additional long-term safety data on
vitamin D (trials of at least 2 years duration) would be
valuable. Ethics committees have often used the tolerable
upper level for vitamin D inappropriately, and this has
hindered research on the safe use of long-term high
doses of vitamin D. There are some signs that the situation
is improving, but ethics committees should be issued with
guidelines regarding the interpretation of safe upper limits
of vitamins in the diet and the use of higher doses of
vitamin D in trials. Further research is also needed to
understand any physiological differences between diet-
ary/supplementary vitamin D2 and D3 (if D2 has to be
used rather than D3), and between dietary D3 and
endogenous sunshine-derived D3. For example, mechan-
isms and rates of absorption might differ in the same
way that half-times of clearance of 25(OH)D2 and
25(OH)D3 from the circulation differ
(58), as might the
rates of clearance of these metabolites into the tissues,
although this requires further research. A careful balance
is needed to ensure that prevalence of deficiency is
reduced without creating concerns about toxicity.
Dietary reference values
As indicated in E. M. S.’s presentation, the SACN is awaiting
the results of research studies, due to be reported by
2010, designed to quantify the relative contribution of
sunlight and dietary sources to circulating concentrations
of 25(OH)D. The recently published research by Cashman
et al.(28,29) offers an excellent starting point for discussion.
Nevertheless, current UK reference values concentrate on
the requirements of large subgroups of the population
(Table 1). These differ from those of other countries
across Europe (Table 2), where the majority have rec-
ommendations to cover a wider range of age groups.
DRI are a system of recommendations from the Institute
of Medicine of the US National Academy of Sciences
used by both the United States and Canada. DRI for vitamin
D have been assessed assuming the absence of adequate
exposure to sunlight, and thus differ from the UK DRV,
where it is assumed that the general population has ade-
quate exposure to UVB from sunshine during the
summer months and no RNI is set; a separate RNI is pro-
vided for those with restricted UVB skin exposure. The
recommendations for 2005 are summarised in Table 4.
A new committee has now been established by the
Institute of Medicine to set the new recommendations for
2010. In addition, the European Food Safety Authority is
in the process of reviewing Europe-wide DRV for micronu-
trients, and plans to hold a consultation in the near future.
Implementation of current guidelines on vitamin D
supplementation
A very significant issue considered by the Forum was con-
cern about the failure of current implementation strategies
in the UK to achieve the current vitamin D recommen-
dations for high-risk groups (pregnant and lactating
women, infants, ethnic minority groups and older
people). There is a lack of awareness of the need to take
Table 4. Dietary reference intakes – recommended intakes for individ-
uals in the USA and Canada(63)
Life stage group Vitamin D (mg/d)*†‡
Infants (months)
0–6 5
7–12 5
Children (years)
1–3 5
4–8 5
Males (years)
9–13 5
14–18 5
19–30 5
31–50 5
51–70 10
. 70 15
Females (Years)
9–13 5
14–18 5
19–30 5
31–50 5
51–70 10
. 70 15
Pregnancy (years)
14–18 5
19–30 5
31–50 5
Lactation (years)
14–18 5
19–30 5
31–50 5
* Values are based on adequate intakes which are believed to cover the needs
of all individuals in the age group, but lack of data or uncertainty in the data
prevents the specification of the percentage of individuals covered by this intake
with confidence (other recommendations are RDA, which are set to meet the
needs of almost all (97–98 %) individuals in a group, or estimated average
requirements, which are expected to meet the requirements of 50 % in a group).
† As cholecalciferol, 1mg cholecalciferol ¼ 40 IU vitamin D.
‡ In the absence of adequate exposure to sunlight.
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supplements among the relevant subgroups of the
population, and health professionals’ knowledge in this
area is considered poor. Health professionals have been
slow to respond to the problem(59). There is an urgent
need to assist health professionals in becoming better
informed about, and motivated towards, the implemen-
tation of these recommendations. Currently, front-line
health professionals do not routinely raise awareness
about the importance of vitamin D status; and this argues
for targeted training of health professionals in this area as
well as a wide-reaching communication strategy from the
Government. It is hoped that efforts from the Department
of Health in connection with Healthy Start will help
to raise awareness among pregnant women and those pro-
fessionals who interact with them. However, this work is
currently directed specifically towards the promotion of
free supplements for pregnant women on income support
(estimated to be about 20 % of the subpopulation) and
their babies and young children aged under 4 years (see
below); low vitamin D status is more widespread than
this and does not, in fact, vary with social class(9).
With the re-emergence of rickets and a considerable
public health burden of low vitamin D status being already
apparent, there is a need for urgent action from policy
makers and risk managers to implement the existing
recommendations. Pregnant women are a recognised
‘high-risk’ group for vitamin D deficiency in the UK, and
vitamin D supplements are recommended throughout
pregnancy. Consideration should be given to providing
recommendations to women of childbearing age about
vitamin D supplementation because many have low
vitamin D status before pregnancy begins, and many preg-
nancies are unplanned. In addition, there is a high preva-
lence of low vitamin D status in the general population
of the UK, which is of concern: for example, 24 % of the
men and 28 % of the women aged 19–24 years have
serum 25(OH)D concentrations below 25 nmol/l(60), and
there is a high prevalence among older people, which is
greatly increased among those in institutional care(8).
Accessibility to vitamin D supplements
A major obstacle to the implementation of the present
dietary recommendations for high-risk subgroups of the
population (i.e. use of supplementary vitamin D) is
the lack of accessibility to affordable supplements. Under
the UK Government’s Healthy Start scheme, pregnant
women and children aged under 4 years are entitled to
free supplements containing vitamin D if the mother is
under the age of 18 years or on income support. Primary
Care Trusts and Health Boards are responsible for
making Healthy Start vitamin supplements available, and
these can also be sold cheaply to those not eligible for
free Healthy Start supplementation. However, several
problems within the supply chain for these supplements
have been reported. There have been problems with
manufacture, and many National Health Service Trusts
do not make the supplements generally available, and
furthermore, not all mothers or indeed health professionals
are aware of the need for vitamin D supplementation. Also,
the supplements are not suitable for those who follow
kosher or halal dietary patterns, and are not on general
sale in pharmacies and retail outlets. Although most
commercial multivitamins contain vitamin D, they are not
appropriate for pregnant women or for older people as
they often contain vitamin A. Furthermore, the available
supplements of vitamin D commonly contain Ca, which
often proves unacceptably constipating. Issues about the
supply of supplements containing vitamin D without
either Ca or vitamin A need to be resolved as a matter of
urgency so that strategies to improve health professionals’
knowledge in this area and to improve provision of
vitamin D to pregnant women can be implemented effec-
tively across the UK as a whole.
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